diabetestalk.net

Diabetes: New Pathway To Treatment Suggested By Protein Culprit

Diabetes: New pathway to treatment suggested by protein culprit

Diabetes: New pathway to treatment suggested by protein culprit

What is the link between anxiety and diabetes? New research shows that a protein related to the development of anxiety and depression may also play a role in triggering diabetes. Scientists from the Max Planck Institutes hypothesize that an antagonist compound could be used to block its effect.
The main known causes for type 2 diabetes so far include obesity and lack of physical exercise — both of which can lead to insulin resistance — as well as a family history of the condition.
Insulin resistance occurs when muscles, liver, and fat cells become unable to use insulin appropriately, which ultimately leads to a dangerous rise in blood glucose levels.
Now, researchers from the Max Planck Institute of Psychiatry in Munich, Germany, have found that a protein called FKBP51 may also play a role in triggering type 2 diabetes.
The protein has so far been associated with anxiety and depression; it contributes to the regulation of the stress system. When the gene that controls the production of FKBP51 suffers a mutation, this can lead to dysregulation of the stress system, which, in turn, can cause mental health disorders.
Mathias Schmidt — lead researcher of the current study — and colleagues have recently noted that the FKBP51 protein also contributes to forming a molecular link between the stress system and the regulation of various metabolic functions. This may make FKBP51 responsible for the onset of metabolic diseases such as obesity and diabetes.
The team's findings have now been published in the journal Nature Communications.
Protein reacts to metabolic stress
Schmid Continue reading

Rate this article
Total 1 ratings
Are You Staying Informed With New Diabetes Treatments?

Are You Staying Informed With New Diabetes Treatments?

Poll finds less than half of health care professionals aware of newest drug up for FDA approval.
By Steve Freed, R.Ph., Diabetes Educator, Publisher
In the past two years, more than 30 medications have come to the market, and more than 475 additional diabetes drugs are in the works to get approved.
To test the knowledge of endocrinologists, 149 endocrinologists responded to a survey about a new drug that the FDA is looking to approve shortly. The drug, ertugliflozin, met the primary outcomes in two year-long phase 3 trials, VERTIS SU and VERTIS SITA2 and only 45% of the physicians said they had heard of the drug. Of those, 20% knew it only by name and only 5% were “very familiar” with it.
Ertugliflozin is an investigational oral sodium-glucose co-transporter 2 (SGLT-2) inhibitor aimed at improving glycemic control in adults. It is expected to be approved before the end of the year, which would make it the fourth drug in its class to market.
Respondents were asked, after reading the clinical trial data provided about the drug and assuming ertugliflozin is approved and performs as described, how long they thought it would take for them to start prescribing. Only 7% answered that they would start prescribing within the first week, another 18% said they would prescribe it in the first month, and nearly half (46%) said they would prescribe it within 2 to 6 months. Just more than 1 in 5 (21%) said they would likely wait at least 9 months before prescribing.
Among the 113 endocrinologists who anticipated prescribing ertugliflozin, the main reason given was efficacy (58% answer Continue reading

How Fresno Man Started Biking and Reversed Type 2 Diabetes

How Fresno Man Started Biking and Reversed Type 2 Diabetes

FRESNO — Jaime Rangel holds a bike tire and begins checking with his hands for thorns and other sharp objects that might be puncturing the tire’s rubber tread. His fingers, stained with black patches of oil, move quickly and seamlessly. He’s done this type of work dozens of times before.
All around him, a steady stream of kids line up to get their bikes’ flat tires and faulty brakes fixed at this free event at a park in southeast Fresno.
The free bike repairs are a preamble to the Cumbia Ride, a group bike ride with Latin American dance music started last year by Fresno’s Cultiva la Salud to promote biking and a healthier lifestyle among Latino families.
Rangel, 26, says he’s here fixing bikes because he relates to many of the young riders at the event — kids who can’t afford to have their bikes repaired.
“When I was a kid, no one showed me how to fix a bike,” he says. “My mom never took me to a bike shop because we grew up low income, so everything I had to learn from scratch.”
Rangel makes a point of showing those skills to the kids and parents lingering by their bikes. He wants young people and adults, especially in working-class neighborhoods like southeast Fresno, to be able to bike more to fend off chronic illnesses such as diabetes.
Rangel speaks from personal experience.
Facing Type 2 Diabetes as a Teen
Rangel was just 14 and living with his family in Los Angeles when he was diagnosed with Type 2 diabetes. Obesity and a sedentary lifestyle are risk factors for the illness. While he was tall — 6-foot-1 — he weighed 260 pounds.
It’s been Continue reading

Diabetes at Work: Your Rights and Benefits

Diabetes at Work: Your Rights and Benefits

By Isabel Chin, Lynn Kennedy, and Jeemin Kwon
Breaking down employer-based health insurance, employee health benefits, and employee rights for people with diabetes
The most common type of health insurance coverage in the US is employer-based insurance, covering almost 50% of all Americans in 2015. Despite its prominence, employer-based health insurance can be challenging to navigate, and living with diabetes makes the process of understanding and accessing employee health benefits like insurance all the more critical. This guide breaks down employer-based insurance, employee health benefits, and the rights of people with diabetes in the workplace.
We hope this guide helps you better understand employer-based insurance, maximize your health through work benefits, and know and protect your workplace rights as a person with diabetes.
In this article, you can read about (click a particular section to jump right to it!):
What to do to maintain employer-based health insurance after a major life event like losing a job
Employer-Based Health Insurance: The Basics
Currently, all US employers with over 50 full-time employees are required to provide health insurance that meets certain standards of affordability otherwise they face a fine. While small businesses are not required to offer health insurance to their employees, many companies will so they can take advantage of tax credits.
It is important to understand what coverage and health benefits your employer offers in order to choose the right insurance plan for you. Job-based health plans are required to provide a “Summary of Be Continue reading

Top 5 natural substances that could cure type 1 diabetes

Top 5 natural substances that could cure type 1 diabetes

(NaturalNews) While type 1 diabetes is not as common as type 2 diabetes, it can be just as devastating. Unlike type 2, which is largely caused by weight gain, poor nutrition, lack of exercise and other controllable risk factors, type 1 diabetes is considered to be an autoimmune disorder and a person is born with it. The beta cells in the pancreas of a type 1 diabetic are not able to manufacture the insulin to control blood sugars in the body. As a result, blood sugars can get dangerously high or low - and quickly. Traditionally, type 1 diabetes is controlled with a combination of insulin injections or an insulin pump as well as careful counting of carbohydrates in regards to activity levels. However, this can be an extremely difficult way to live, especially for children. There, are, however, natural substances which have the potential to treat this condition. Read on to find out more.
Arginine
Arginine is an amino acid and is available in most health food stores as a nutritional supplement. In a 2007 study, it was found that regular use of arginine in laboratory animals was able to stimulate the pancreas to produce beta cells, the special kind of pancreatic cells which produce insulin.
Goldenseal
Goldenseal is an herb with a long history of medicinal use both in the East and the West. Modern science believes that part of its value as a treatment lies in the fact that it contains berberine, a bioactive compound. Berberine has been shown in studies on laboratory animals to, like arginine, stimulate the production of the pancreatic beta cells which the body needs to make insu Continue reading

No more pages to load

Popular Articles

  • New Stem Cell Treatment, Successful in Mice, May Someday Cure Type 1 Diabetes

    When his infant son Sam was diagnosed with type 1 diabetes two decades ago, Doug Melton made himself a promise: He would cure it. When his daughter Emma was diagnosed with the same autoimmune disease at 14, he redoubled his efforts. Finally he can see the finish line. In a paper published Thursday in the journal Cell, Melton announces that he has created a virtually unlimited supply of the cells t ...

  • New Self-Administering ‘Smart’ Insulin Could Revolutionise Diabetes Treatment

    This new form of ‘smart’ insulin remains in the blood stream for 24 hours, and maintains blood sugar levels on its own. Which means no more finger pricks or insulin pens. Researchers in the US have developed a new type of insulin that’s injected once a day into the blood-stream, and then is automatically activated only when a person’s blood sugar levels are high enough. This means a type 1 ...

  • New Stem Cell Treatment "Switches Off" Type 1 Diabetes

    For those with type 1 diabetes, regularly injecting themselves with insulin is part and parcel of their daily lives. This form of treatment hasn’t advanced much for nearly a century, so it will come as good news that researchers at the Massachusetts Institute of Technology (MIT) are on the verge of a breakthrough. As a study in Nature Medicine reveals, insulin-producing beta cells made from huma ...

  • New type 2 diabetes treatment 'easier, cheaper' option

    About 20,000 Australians suffering type 2 diabetes will be able to swap twice daily injections for a weekly treatment, and save around $1,600 per year under a new medicine to be placed on the Pharmaceutical Benefits Scheme (PBS). Federal Health Minister Sussan Ley announced the new diabetes treatment Exanatide will be subsidised under the PBS from September 1, along with an extra $70 million inves ...

  • New measure of insulin-making cells could gauge diabetes progression, treatment

    Researchers at the University of Wisconsin–Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin. In a study published in the August edition of the journal Diabetes, Weibo Cai, Matthew J. Merrins and colleagues used a PET scanner to detect minute levels of a radioactive chemical in the mouse pancreas. Cai, the senio ...

  • New diabetes treatment teaches rogue immune cells to behave

    FRIDAY, July 14, 2017 -- A treatment targeting wayward immune cells in people with type 1 or type 2 diabetes may help even years later, a new study finds. For the treatment, researchers take blood from a person with diabetes and separate out the immune system cells (lymphocytes). They briefly expose those cells to stem cells from umbilical cord blood from an unrelated infant. Then they return the ...

  • #51: Diabetes treatment in 2017: New meds, insulin, and cardiac risk reduction

    Get cozy with these new drugs for diabetes treatment. Don’t be scared, they won’t bite. On this episode, we interview Endocrinologist and current president of AACE, Dr. Jonathan D. Leffert, MD, FACP, FACE, ECNU about how to utilize the myriad of new diabetes drugs on the marketplace including SGLT2 inhibitors, DPP4 inhibitors, GLP1 agonists, and new ultra long acting insulins. Plus, we’ll te ...

  • Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment

    Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment Peptide immunotherapy offers a more nuanced approach that may reduce the risk for adverse effects in persons with type 1 diabetes. Type 1 diabetes is characterized by the autoimmune destruction of pancreatic beta cells, leading to progressively decreasing i ...

  • Fiasp, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults

    Fiasp, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults Bagsvrd, Denmark (ots/PRNewswire) - Canada first country to launch Fiasp This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, Novo Nordisk announced that Fiasp, a new, fast-acting mealtime insulin for the treatment of ...

Related Articles